Pharmakologische Intervention bei Patienten mit Osteoporose

• Literatur

• 1 Balena R. et al. Effects of different regimens of sodium fluoride treatment for osteoporosis on the structure, remodelling and mineralization of bone. Osteoporos Int 1998; 8 (05) 428-435.
• 2 Cauley JA. et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65 (02) 125-134.
• 3 Chapuy MC. et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992; 327 (23) 1637-1642.
• 4 Chesnut CD. et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fracture study. PROOF Study Group. Am J Med 2000; 109 (04) 267-276.
• 5 Dieli F. et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003; 102 (06) 2310-2311.
• 6 Dukas L. et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52 (02) 230-236.
• 7 Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007; 4 (01) 42-55.
• 8 Ettinger B al. Reduction of vertebral fracture in postmenopausal women with osteoporosis reated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999; 282 (07) 637-645.
• 9 Felsenberg D. et al. Kiefernekrosen nach hoch do-sierter Bisphosphonattherapie. Dtsch Arztebl 2006. 103:(46)A-3078/B-2681/C-2572
• 10 Fox J. et al. Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: a study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuronal Interact 2005; 5 (04) 356-357.
• 11 Kanis JA. Calcium requirements for optimal skeletal health in women. Calcif Tissue Int 1991; 49 (Suppl.) 33-41.
• 12 Maricic M. et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002; 162 (10) 1140-1143.
• 13 Marie PJ. et al. Mechanism of action and therapeuti-cal potential of strontium in bone. Calcif Tissue Int 2001; 69: 121-129.
• 14 Meunier PJ. et al. The effect of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 2004; 350 (05) 459-468.
• 15 Neer RM. et al. Effect of parathyroid hormone (1-34.) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344 (19) 1434-1441.
• 16 Pfeifer M. et al. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15 (06) 1113-1138.
• 17 WHI writing Group Risks and Benefits of Estrogen plus Progestin in healthy postmenopausal women. JAMA 2002; 288 (03) 321-332.
• 18 Woo S-B. et al Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws. Ann Intern Med 2006; 144: 753-761.